

PRESS RELEASE



Martin Driscoll to Serve as an Adviser to Siva

AUSTIN, TEXAS, December 30, 2021 – Siva Therapeutics, Inc. (“Siva”) is pleased to announce that Martin Driscoll has agreed to serve as an adviser to Siva. As part of this effort, Mr. Driscoll will provide periodic input and strategic advice to the Siva management team on key development, financing, and operational matters related to the company’s business.

Mr. Driscoll has more than 40 years of experience in the biopharmaceutical industry. Including his current role as chief executive officer at OncoNano Medicine, Inc., Marty has served as the chief executive officer of multiple biopharmaceutical development companies, including two publicly traded firms. Marty’s career in the industry has included deep experience in biopharmaceutical product development, commercialization, financing for both private and public companies, M&A, and business development transactions. Mr. Driscoll has also served as a director on the boards of multiple public and private companies. Mr. Driscoll received a B.Sc. in Communications from the University of Texas at Austin.

“We’re delighted to have Marty agree to serve as an adviser to Siva.” said Len Pagliaro, PhD, CEO of Siva. “He brings great breadth and depth of oncology background as well as extensive oncology business experience to our team. Marty’s acumen and insight will be valuable assets for Siva as we move toward the clinic.”

“I look forward to sharing my thoughts and ideas with Dr. Pagliaro and the Siva management team as they further develop the core technology at the company,” said Martin Driscoll. “I hope my many years of experience in building and operating biopharmaceutical development companies can

benefit Siva. I want to be a beneficial participant in the continued expansion of the dynamic life sciences development ecosystem in Texas.”



Siva Therapeutics Inc is developing Targeted Hyperthermia™, a photothermal cancer therapy, which uses therapeutic heat to treat solid cancers. The heat is delivered to tumors by infrared light that is absorbed by SivaRods™ gold nanorods in the tumor and re-emitted as heat. Therapeutic heat (44°C) stimulates the immune system, shrinks tumors, inactivates cancer stem cells, and increases tumor perfusion – thus enabling drugs to reach all tumor compartments more effectively. The size, shape, and surface chemistry of the nanorods target the leaky vasculature of solid tumors, and the selective thermal sensitivity of tumor tissue enables the therapy to deliver clean margins. Targeted Hyperthermia promises to be safe, effective, minimally invasive, competitive in cost, and a valuable adjunct to drug therapy and other cancer treatments. Siva’s initial clinical targets include colorectal, esophageal, and pancreatic cancers.

Contact us at info@sivatherapeutics.com or visit: www.sivatherapeutics.com